SA519410244B1 - تعبير مُحور جينياً انتقائي للنسيج - Google Patents

تعبير مُحور جينياً انتقائي للنسيج

Info

Publication number
SA519410244B1
SA519410244B1 SA519410244A SA519410244A SA519410244B1 SA 519410244 B1 SA519410244 B1 SA 519410244B1 SA 519410244 A SA519410244 A SA 519410244A SA 519410244 A SA519410244 A SA 519410244A SA 519410244 B1 SA519410244 B1 SA 519410244B1
Authority
SA
Saudi Arabia
Prior art keywords
transgene
transgene expression
selective expression
tissue selective
selective transgene
Prior art date
Application number
SA519410244A
Other languages
Arabic (ar)
English (en)
Inventor
ديفيد اوبيركوفلير
ستفانى تاجلياتيلا
كارتيك رامامورثى
سزو- ينج شين
اندريو يونج
Original Assignee
انكوديد ثيرابيتوتيكس إنك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by انكوديد ثيرابيتوتيكس إنك filed Critical انكوديد ثيرابيتوتيكس إنك
Publication of SA519410244B1 publication Critical patent/SA519410244B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Environmental Sciences (AREA)
SA519410244A 2017-04-03 2019-10-03 تعبير مُحور جينياً انتقائي للنسيج SA519410244B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762480998P 2017-04-03 2017-04-03
PCT/US2018/025940 WO2018187363A1 (en) 2017-04-03 2018-04-03 Tissue selective transgene expression

Publications (1)

Publication Number Publication Date
SA519410244B1 true SA519410244B1 (ar) 2024-05-29

Family

ID=63713399

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519410244A SA519410244B1 (ar) 2017-04-03 2019-10-03 تعبير مُحور جينياً انتقائي للنسيج

Country Status (20)

Country Link
US (6) US10287608B2 (enExample)
EP (2) EP3607073B1 (enExample)
JP (2) JP7246359B2 (enExample)
KR (1) KR102604159B1 (enExample)
CN (2) CN110730823B (enExample)
AU (1) AU2018250161B2 (enExample)
BR (1) BR112019020777A2 (enExample)
CA (1) CA3058189A1 (enExample)
CL (2) CL2019002805A1 (enExample)
CO (1) CO2019011450A2 (enExample)
EA (1) EA201992358A1 (enExample)
ES (1) ES2981970T3 (enExample)
IL (1) IL269767A (enExample)
MA (1) MA71412A (enExample)
MX (4) MX2019011772A (enExample)
PL (1) PL3607073T3 (enExample)
SA (1) SA519410244B1 (enExample)
SG (1) SG11201909203WA (enExample)
TW (3) TW202315946A (enExample)
WO (1) WO2018187363A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
EP3201339A4 (en) 2014-10-03 2018-09-19 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
KR102422625B1 (ko) 2015-10-09 2022-07-20 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
KR102604132B1 (ko) 2015-12-14 2023-11-17 콜드스프링하버러보러토리 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
TW202315946A (zh) 2017-04-03 2023-04-16 美商編碼製藥公司 組織選擇性轉基因表現
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
BR112020010883A2 (pt) 2017-12-01 2020-11-10 Encoded Therapeutics, Inc. proteínas de ligação a dna engenheiradas
AU2019253700B2 (en) * 2018-04-09 2025-08-14 Allen Institute Rescuing voltage-gated sodium channel function in inhibitory neurons
EP3788169A4 (en) 2018-05-04 2022-08-10 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
JP7695192B2 (ja) * 2018-10-08 2025-06-18 アレン インスティテュート 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP7590962B2 (ja) * 2018-11-05 2024-11-27 アレン インスティテュート 皮質興奮性ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP7724157B2 (ja) * 2019-02-05 2025-08-15 ザ・ブロード・インスティテュート・インコーポレイテッド ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤
AU2020228028A1 (en) * 2019-02-25 2021-09-30 University Of Massachusetts DNA-binding domain transactivators and uses thereof
AU2020245425A1 (en) * 2019-03-22 2021-10-07 Encoded Therapeutics, Inc. Multiplexing regulatory elements to identify cell-type specific regulatory elements
SG11202113048SA (en) * 2019-05-29 2021-12-30 Encoded Therapeutics Inc Compositions and methods for selective gene regulation
MX2022014151A (es) 2020-05-11 2022-11-30 Stoke Therapeutics Inc Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades.
US12173304B2 (en) 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
EP4591708A2 (en) * 2020-07-08 2025-07-30 Baylor College of Medicine Gene therapy for stxbp1 encephalopathy
IL298856A (en) * 2020-07-09 2023-02-01 Modalis Therapeutics Corp A method for treating Alzheimer's disease by targeting the MAPT gene
AR123041A1 (es) * 2020-07-24 2022-10-26 Univ Massachusetts Transactivadores del dominio de unión al adn y usos de los mismos
AU2022378524A1 (en) * 2021-10-28 2024-05-02 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
WO2025212993A1 (en) * 2024-04-05 2025-10-09 Encoded Therapeutics, Inc. Materials and methods for trangene expression in neural cells

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405A (en) * 1850-05-28 John weidman
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
NZ333334A (en) 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
AU746454B2 (en) 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6303370B1 (en) 1998-03-24 2001-10-16 Mayo Foundation For Medical Education And Research Tissue-specific regulatory elements
CA2246005A1 (en) 1998-10-01 2000-04-01 Hsc Research And Development Limited Partnership Hybrid genes for gene therapy in erythroid cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6649371B1 (en) 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
EP2112234A3 (en) 1999-11-26 2010-06-16 McGill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
AU776576B2 (en) 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
EP1287134B1 (en) 2000-06-07 2007-08-01 Ortho-McNeil Pharmaceutical, Inc. The human voltage-gated sodium channel beta-1a subunit and methods of use
AUPR492201A0 (en) 2001-05-10 2001-06-07 Bionomics Limited Novel mutation
EP1402043A1 (en) 2001-07-03 2004-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
AU2003219933A1 (en) 2002-02-25 2003-09-09 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US20070107071A1 (en) 2003-01-28 2007-05-10 Sebastien Couillard-Despres Use of regulatory sequences for specific, transient expression in neuronal determined cells
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
US7094600B2 (en) 2003-06-26 2006-08-22 The Research Foundation Of State University Of New York Screen for sodium channel modulators
EP1747277B1 (en) 2004-04-14 2011-08-10 Agency for Science, Technology and Research Gene delivery to neuronal cells
TWI293307B (en) 2004-09-30 2008-02-11 Ind Tech Res Inst A liver-specific chimeric regulatory sequence and use thereof
EP2021499A4 (en) 2005-12-16 2010-02-17 Univ Leland Stanford Junior FUNCTIONAL ARRAYS FOR THE IDENTIFICATION OF ELEMENTS FOR GENE PRESSION REGULATION WITH HIGH THROUGHPUT
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
EP1993477A4 (en) 2006-01-20 2010-03-03 Univ California TRANSPLANTATION OF NERVE CELLS
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
US20100297674A1 (en) 2008-01-22 2010-11-25 Chromocell Corporation NOVEL CELL LINES EXPRESSING NaV AND METHODS USING THEM
US20110165129A1 (en) 2008-05-06 2011-07-07 Arnold Kriegstein Ameliorating Nervous Systems Disorders
EP2321417B1 (en) * 2008-08-20 2015-07-15 Brainco Biopharma, S.L. Stxbp1 as psychiatric biomarker in murine model system and its uses
WO2010037143A1 (en) 2008-09-29 2010-04-01 The University Of Montana Vectors and methods of treating brain seizures
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
US20110135611A1 (en) 2009-12-03 2011-06-09 The J. David Gladstone Institutes Methods for treating apolipoprotein e4-associated disorders
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
WO2011139349A1 (en) 2010-05-03 2011-11-10 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
ES2863526T3 (es) 2010-06-23 2021-10-11 Curna Inc Tratamiento de enfermedades relacionadas con la subunidad alfa del canal de sodio (SCNA), controlado por voltaje, mediante inhibición de la transcripción antisentido natural a SCNA
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2655621B1 (en) * 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
ES2685611T3 (es) 2011-02-14 2018-10-10 The Children's Hospital Of Philadelphia Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
JP6373763B2 (ja) 2012-02-17 2018-08-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法
AU2013201287B2 (en) 2012-03-06 2015-05-14 Duke University Synthetic regulation of gene expression
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2014144486A2 (en) 2013-03-15 2014-09-18 The Children's Hospital Of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
EP3622821A1 (en) 2013-05-15 2020-03-18 Regents of the University of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
WO2015143046A2 (en) 2014-03-18 2015-09-24 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
WO2015188065A1 (en) * 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
WO2016172155A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
CN104846015B (zh) 2015-05-27 2018-03-27 深圳先进技术研究院 特异性兴奋伏隔核中的gaba能神经元的组合物及其在改善精神分裂症异样行为中的应用
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
MX2018004755A (es) 2015-10-29 2018-12-19 Voyager Therapeutics Inc Entrega de polinucleotidos dirigidos al sistema nervioso central.
TW202315946A (zh) 2017-04-03 2023-04-16 美商編碼製藥公司 組織選擇性轉基因表現

Also Published As

Publication number Publication date
MX2022015604A (es) 2023-02-09
US20190024120A1 (en) 2019-01-24
US10287607B2 (en) 2019-05-14
AU2018250161A1 (en) 2019-10-17
AU2018250161B2 (en) 2024-04-04
TW202315946A (zh) 2023-04-16
EP3607073B1 (en) 2024-06-05
EP3607073A1 (en) 2020-02-12
TW201842185A (zh) 2018-12-01
KR102604159B1 (ko) 2023-11-20
MX2022015605A (es) 2023-02-09
IL269767A (en) 2019-11-28
US20200165628A1 (en) 2020-05-28
US20190024118A1 (en) 2019-01-24
JP7246359B2 (ja) 2023-03-27
US20230203531A1 (en) 2023-06-29
TWI808079B (zh) 2023-07-11
SG11201909203WA (en) 2019-11-28
US10519465B2 (en) 2019-12-31
CN110730823B (zh) 2023-12-29
TWI848486B (zh) 2024-07-11
US20190024121A1 (en) 2019-01-24
JP7477675B2 (ja) 2024-05-01
EP3607073A4 (en) 2020-12-30
CO2019011450A2 (es) 2019-10-31
JP2020515292A (ja) 2020-05-28
MX2022015603A (es) 2023-02-09
US20190024119A1 (en) 2019-01-24
CL2019002805A1 (es) 2020-03-06
KR20190137126A (ko) 2019-12-10
CL2023000294A1 (es) 2023-08-25
EA201992358A1 (ru) 2020-03-24
WO2018187363A1 (en) 2018-10-11
CA3058189A1 (en) 2018-10-11
JP2023072039A (ja) 2023-05-23
MA71412A (fr) 2025-04-30
CN110730823A (zh) 2020-01-24
ES2981970T3 (es) 2024-10-14
EP4403642A2 (en) 2024-07-24
CN117821509A (zh) 2024-04-05
MX2019011772A (es) 2020-01-09
US10287608B2 (en) 2019-05-14
PL3607073T3 (pl) 2024-09-30
EP4403642A3 (en) 2024-10-09
TW202315945A (zh) 2023-04-16
BR112019020777A2 (pt) 2020-04-28

Similar Documents

Publication Publication Date Title
SA519410244B1 (ar) تعبير مُحور جينياً انتقائي للنسيج
HUS2500003I1 (hu) Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
MX2019013312A (es) Composiciones para facilitar la fusion de membranas y usos de estas.
MX2022009512A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
WO2016012544A3 (en) Enhanced reprogramming to ips cells
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
MX2017010746A (es) Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas.
GB2557123A (en) Modified cells and methods of therapy
EP4620521A3 (en) Methods and compositions relating to chondrisomes from cultured cells
SG10201811116UA (en) Non-human animals having a humanized programmed cell death 1 gene
NZ741778A (en) Multiplexed genome editing
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
PH12013502605B1 (en) Methods and compositions for selective regulation of protein expression
ZA202004679B (en) Regeneration of genetically modified plants
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
MX2016016756A (es) Terapia con células madre en patologías endometriales.
NZ726355A (en) Humanized dipeptidyl peptidase iv (dpp4) animals
MX2018011534A (es) Metodos para transfectar plantas y para reducir eventos de integracion aleatoria.
PH12017500695A1 (en) Herbicide tolerance genes and methods of use thereof
PH12016501447A1 (en) Zea mays regulatory elements and uses thereof
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
WO2013012889A3 (en) Regulatory polynucleotides and uses thereof
PH12017501972B1 (en) Fungicidal composition and method for controlling plant diseases
BR112018069498A2 (pt) composições e métodos para repelir e matar carrapatos e desprender carrapatos em alimentação
WO2016133792A3 (en) Structure and function of salicylic acid binding sites on human hmgb1 and methods of use thereof